Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen
- 1 October 2008
- journal article
- other
- Published by Wolters Kluwer Health in AIDS
- Vol. 22 (15) , 2045-2046
- https://doi.org/10.1097/qad.0b013e32830f4c7d
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Raltegravir treatment response in an HIV-2 infected patient: a case reportAIDS, 2008
- In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2008
- Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In VitroAntimicrobial Agents and Chemotherapy, 2008
- Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patientsAIDS, 2008
- Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure ProphylaxisAntiviral Therapy, 2004